The input parameters to the model were as follows:
the probability of mild or no CMV disease in the first year; the probability of death from mild or no CMV disease in the first year; the probability of surviving mild or no CMV disease in the first year; the annual probability of hospital readmission after the first year; and the probability of death after the first year.
Study designs and other criteria for inclusion in the review
The main study used was a randomised double-blind, placebo-controlled trial, details of which have been published (see Other Publications of Related Interest). This trial was used to estimate the probability data for the model, and was supplemented by additional follow-up of some of the trial patients. The life expectancy data were estimated from a longitudinal study.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Two primary studies were included in the review.
Methods of combining primary studies
For variables that were not statistically significantly different between the intervention and the comparator, the weighted averages of the CMVIG and placebo data from the single trial were calculated. These used the inverse of the variants as weights. The Markov model was used to combine the probability and life expectancy data. No other methods to combine the data were reported. the probability of mild or no CMV disease in the first year was 0.88 for CMVIG and 0.74 for placebo; the probability of death from mild or no CMV disease in the first year was 0.13 for CMVIG and 0.13 for placebo; the probability of surviving mild or no CMV disease in the first year was 0.87 for CMVIG and 0.87 for placebo; the annual probability of hospital readmission after the first year was 0.305 for CMVIG and 0.305 for placebo; and the probability of death after the first year was 0.074 for CMVIG and 0.074 for placebo.
Measure of benefits used in the economic analysis
The measure of health benefit used in the economic analysis was life-years saved.
Direct costs
Resource quantities and unit costs were not reported separately for most of the cost items included in the analysis. The direct costs included the hospital inpatient and outpatient services and the drug costs. The variable cost data were derived from the observed resource use and service use for 66 of the 141 patients enrolled in the CMVIG clinical trial, the main source used to estimate the effectiveness. The two hospitals contributing cost data used the transition I-Clinical Cost Manager Cost Manger cost-accounting software, which tracks the individual expenses related to each hospital according to the category. The costs included were for admission for liver transplantation, organ acquisition, the operating room, intensive care and the regular hospital room, nursing care, laboratory and radiology tests, and pharmacy costs.
The authors reported that, at the time of the CMVIG trial, the outpatient expenses were not recorded, and thus, were unavailable for patients who participated in the study. The annual outpatient costs were derived from patients who underwent OLT at the New England Medical Centre during the fiscal year 1993. The average annual expenses were $16,400 for clinic visits and immunosuppressive treatment with cyclosporin A, based on a dose of 10 mg/kg/day. The cost of CMVIG was estimated at $13,600, using 1998 wholesale drug costs for a 70-kg person over the first 4 months after transplant. The cost of readmissions was estimated at an average cost of $7,800 per year, from patients enrolled in the CMVIG trial (1993) at the New England Medical Centre. The price year was 1999. The costs were changed to 1999 US dollars using the adjusted indices of the medical care component of the US Consumer Price Index. The costs were discounted at a rate of 3% and 5% per annum.
Statistical analysis of costs
Two sided t-tests were used to compare continuous variables, while chi-squared tests were used to compare proportions. The expected costs were calculated using multiple regression analysis (SPSS/PC+ software). The following variables were assessed as potential predictors of the costs: the length of stay before transplantation; the cumulative length of stay for transplantation after the first year; the drug (CMVIG or placebo); survival status; and the presence of one or more of the following, severe CMV-associated disease, CMV viremia, any opportunistic infection or invasive fungal disease.
